| BOEHRINGER INGELHEIM INTERNATIONAL GMBH Patent applications |
| Patent application number | Title | Published |
|---|
| 20150315180 | INHIBITORS OF CYTOMEGALOVIRUS - Compounds of Formula (I) wherein n, R | 11-05-2015 |
| 20150291592 | HEPATITIS C INHIBITOR COMPOUNDS - Compounds of Formula (I) wherein n, X | 10-15-2015 |
| 20150283341 | METHOD, ELECTRONIC DEVICE, INHALATION TRAINING SYSTEM AND INFORMATION STORAGE MEDIUM FOR PRACTICING AND/OR CONTROLLING AN INHALATION PROCESS OF A PATIENT - A method, an electronic device, a system and an information storage medium for practicing and/or controlling an inhalation process of a patient. The method involves quantifying an airflow in a mouthpiece of an inhaler during an inhalation process of the patient using an inhalation training device, evaluating an airflow signal received from the inhalation training device via an electronic device and providing visual feedback to the patient with the electronic device, the visual feedback varying with one or more time-variant characteristics of the evaluated airflow signal. The electronic device is configured for evaluation of an airflow signal received from an inhalation training device and for provision of visual feedback to the patient, the visual feedback varying with one or more time-variant characteristics of the evaluated signal. The inhalation training system comprises an inhalation training device, an inhaler and the electronic device. | 10-08-2015 |
| 20150283337 | INHALATION TRAINING DEVICE AND SYSTEM FOR PRACTICING OF AN INHALATION PROCESS OF A PATIENT - An inhalation training device and inhalation training system for practicing of an inhalation process of a patient. The inhalation training device has a that is housing attachable to and detachable from a mouthpiece of an inhaler designed to provide a drug to the patient and a microphone adapted to measure the airflow occurring in the mouthpiece of the inhaler during an inhalation process of the patient. The inhalation training system includes the inhalation training device, an inhaler and an electronic device configured for evaluation of a signal received from the inhalation training device and for visual and/or audio feedback to the patient. | 10-08-2015 |
| 20150232484 | FUSED THIAZIN-3-ONES AS KCA3.1 INHIBITORS - The present invention encompasses compounds of the formulas (I) & (II), wherein the groups A, L and Ar are defined as in claim | 08-20-2015 |
| 20150158861 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS - Compounds of Formula (I) wherein n, m, R | 06-11-2015 |
| 20150148322 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA - The invention relates to novel piperidino-dihydrothienopyrimidine sulfoxides of formula I, | 05-28-2015 |
| 20150122247 | NEBULISER WITH CODING MEANS - A nebuliser and a housing part removably connected thereto, each having a coding, are proposed. To increase the flexibility in the coding while using carry-over parts at least one of the coding means can be mounted in different defined positions on the nebuliser or the housing part removably connected thereto so that in each position a different coding is obtained in which the coding means match one another. | 05-07-2015 |
| 20150118225 | ANTICOAGULANT ANTIDOTES - The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants. | 04-30-2015 |
| 20150105397 | Piperazine derivatives and the use thereof as medicament - The present inventions relate to substituted piperazine derivatives of general formula (I) | 04-16-2015 |
| 20150087829 | PROCESS AND INTERMEDIATES FOR PREPARING GPR40 AGONISTS - The present invention relates to compounds of formula I | 03-26-2015 |
| 20150080366 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS - Compounds of Formula (I) wherein n, A, R | 03-19-2015 |
| 20150057295 | New 6-Alkynyl Pyridine - This invention relates to 6-alkynyl-pyridine of general formula (I) | 02-26-2015 |
| 20150057286 | NEW BIS-AMIDO PYRIDINES - This invention relates to bis-amido pyridines of general formula (I) | 02-26-2015 |
| 20150051208 | PYRIDINONES - The present invention encompasses compounds of general formula (I) | 02-19-2015 |
| 20150045376 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA - Piperidino-dihydrothienopyrimidine sulfoxides of formula I | 02-12-2015 |
| 20150045326 | NOVEL PYRAZINE AMIDE COMPOUNDS - The present invention relates to compounds of formula 1 or pharmaceutically acceptable salt thereof, | 02-12-2015 |
| 20150041558 | NEBULIZER - A nebulizer and a housing part for a nebulizer are proposed, wherein a container containing the fluid to be nebulized is provided. The container is moveable back and forth for conveying and nebulization of the fluid. A securing device forms a transportation lock for holding the container unmovable in a delivery state with closed transportation lock. A control part opens the transportation lock by means of at least one rib or arm when the control part is moved towards the securing device. The securing device comprises a ring-like holding part with inwardly extending holding elements for holding the container inseparably. | 02-12-2015 |
| 20150040893 | NEBULIZER - A nebulizer is proposed which comprises a blocking device for blocking opening of the nebulizer in a tensioned state. The nebulizer comprises preferably an indicator device for indicating a tensioned state of the nebulizer. The nebulizer comprises further a depressible actuator member at a housing part which is detachable from the nebulizer. | 02-12-2015 |
| 20150040890 | NEBULIZER - A nebulizer and a housing part comprising a blocking device as well as use of a blocking device are proposed. The blocking device blocks a rotatable element of a counter device in a defined rotational position until the nebulizer is closed. | 02-12-2015 |
| 20150038731 | PROCESS FOR PREPARING CARBOXYLIC ACIDS - The present invention relates to a process of making a compound of formula (XII) or (XIIA): wherein R | 02-05-2015 |
| 20150038532 | Pharmaceutical Composition Of A Potent HCV Inhibitor For Oral Administration - A pharmaceutical composition of the following Compound (1), a potent hepatitis C viral (HCV) inhibitor, or a pharmaceutically acceptable salt thereof, for oral administration. | 02-05-2015 |
| 20150031699 | TREATMENT OF MYELODYSPLASTIC SYNDROME - The present invention relates to the use of Volasertib or a pharmaceutically acceptable salt thereof or the hydrate thereof for treating myelodysplastic syndrome (MDS). | 01-29-2015 |
| 20150031643 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME II - The present invention relates to the use of Volasertib or a salt thereof or the hydrate thereof in combination with Azacitidine or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). | 01-29-2015 |
| 20150031642 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME I - The present invention relates to the use of Volasertib or a salt thereof or the hydrate thereof in combination with Decitabine or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). | 01-29-2015 |
| 20150025089 | PROCESS FOR THE PREPARATION OF CHIRAL 8-(3-AMINOPIPERIDIN-1-YL)-XANTHINES - The invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines. | 01-22-2015 |
| 20150025088 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS - The invention relates to novel 6-Cycloalkyl-pyrazolopyrimidinones according to formula (I). | 01-22-2015 |
| 20150025065 | NEW AZABENZIMIDAZOLE DERIVATIVES - The present invention relates to compounds of general formula I, | 01-22-2015 |
| 20150018555 | NOVEL CHIRAL NITROGEN-PHOSPHORUS LIGANDS AND THEIR USE FOR ASYMMETRIC HYDROGENATION OF ALKENES - The invention relates to a series of novel chiral nitrogen-phosphorus ligands of formulae (Ia) and (Ib): | 01-15-2015 |
| 20150018334 | INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to aryl pyrazoles, and pharmaceutically acceptable salts thereof. The aryl pyrazoles of the present invention are useful as inhibitors of leukotriene A | 01-15-2015 |
| 20150018333 | INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to compounds of formula (I): | 01-15-2015 |
| 20150018315 | NOVEL TETRA- AND PENTASUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS - The present invention relates to compounds of general formula (I) | 01-15-2015 |
| 20150018314 | NOVEL BENZIMIDAZOLIUM COMPOUNDS - The present invention relates to compounds of general formula (I) | 01-15-2015 |
| 20150018313 | NOVEL 5-SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS - The present invention relates to compounds of general formula (I) | 01-15-2015 |
| 20150015886 | METHOD FOR THE EVALUATION OF THE COLLOIDAL STABILITY OF LIQUID BIOPOLYMER SOLUTIONS - The invention concerns the field of biomolecule formulation screening and stability testing. It concerns a method for the evaluation of the colloidal stability of liquid biopolymer solutions. The present invention describes a method for determining the stability of a liquid pharmaceutical composition comprising: a) providing a liquid pharmaceutical composition in a container, b) shaking said container on a shaker, whereby the shaker performs an oloid movement, c) determining the stability of said liquid pharmaceutical composition. | 01-15-2015 |
| 20150011535 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING THEM, USE AND PROCESSES FOR THE PREPARATION THEREOF - The present invention relates to compounds of general formula (I) | 01-08-2015 |
| 20150011531 | INHIBITORS OF HIV REPLICATION - Compounds of formula (I) and pharmaceutical compositions thereof: wherein A | 01-08-2015 |
| 20150010574 | ANTI-IGF ANTIBODIES - Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer. | 01-08-2015 |
| 20140378504 | METHOD OF USING SUBSTITUTED 2-AZA-BICYCLO[2.2.2]OCTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C - This invention relates to 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 | 12-25-2014 |
| 20140378398 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS - The invention relates to a pharmaceutical combination comprising the compound of formula I | 12-25-2014 |
| 20140377265 | ANTICOAGULANT ANTIDOTES - The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants. | 12-25-2014 |
| 20140371243 | MEDICAL USE OF A DPP-4 INHIBITOR - The present invention relates to the use of a certain DPP-4 inhibitor along with angioplasty or stenting, and/or to its use for treating and/or preventing restenosis from angioplasty or stenting. | 12-18-2014 |
| 20140371226 | 9-[4-(3-CHLORO-2-FLUORO-PHENYLAMINO)-7-METHOXY-QUINAZOLINE-6-YLOXY]-1,4-DI- AZA-SPIRO[5.5]UNDECANE-5-ONE DIMALEATE, USE THEREOF AS A MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF - The present invention relates to a compound of formula (I), | 12-18-2014 |
| 20140371205 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER - The present invention encompasses compounds of general formula (1) | 12-18-2014 |
| 20140363444 | Anti-IL-23 Antibodies - The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same. | 12-11-2014 |
| 20140357646 | POLYMORPHS - The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament. | 12-04-2014 |
| 20140350035 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR- ANTAGONISTS - The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors ( | 11-27-2014 |
| 20140350025 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS - The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones of formula (I), | 11-27-2014 |
| 20140350022 | Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment - The present invention relates to a beneficial treatment of tumours in patients suffering from NSCLC, and to a clinical marker useful as as predictive variable of the responsiveness of tumours in patients suffering from NSCLC. The present invention further relates to a method for selecting patients likely to respond to a given therapy, wherein said method optionally comprises the use of a specific clinical marker. The present invention further relates to a method for delaying disease progression and/or prolonging patient survival of NSCLC patients, wherein said method comprises the use of a specific clinical marker. | 11-27-2014 |
| 20140343105 | NOVEL ORALLY ADMINISTERED DABIGATRAN FORMULATION - The invention relates to a new medicament formulation of the active substance dabigatran etexilate of formula I | 11-20-2014 |
| 20140343083 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof - Pyrrolidine derivatives which are inhibitors of acetyl-CoA carboxylase(s) and their use in the treatment of obesity and type-2 diabetes. An exemplary compound is 2-(4-(1-[5-Chloro-6-(2-hydroxy-2-methyl-propoxy)-pyrimidin-4-yl]-(R)-pyrrolidin-3-yloxy)-phenyl)-N-cyclopropyl-propionamide. | 11-20-2014 |
| 20140343077 | HEPATITIS C INHIBITOR COMPOUNDS - A compound of formula (I) useful for the treatment or prevention of hepatitis C viral infection, (Formula (I)) wherein: X | 11-20-2014 |
| 20140343065 | New Somatostatin receptor subtype 4 (SSTR4) agonists - 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. | 11-20-2014 |
| 20140343014 | COMBINATION OF A CERTAIN DPP-4 INHIBITOR AND VOGLIBOSE - The present invention relates to the use of a combination of a certain DPP-4 inhibitor and an alpha-glucosidase inhibitor for use in therapy, e.g. for use in treating and/or preventing a metabolic disease such as type 2 diabetes mellitus and/or conditions related thereto. The invention also relates to the use of such combination for improving body weight control, reducing body weight, inducing satiety, inhibiting gastric emptying and/or reducing food intake, in a patient in need thereof. | 11-20-2014 |
| 20140341926 | METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER - The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m | 11-20-2014 |
| 20140336405 | Process for preparing spiro[2.5]octane-5,7-dione - Disclosed is a method for the synthesis of spiro[2.5]octane-5,7-dione useful as intermediate in the manufacture of pharmaceutically active ingredients. Also disclosed are novel intermediates used in the synthesis of this compound. | 11-13-2014 |
| 20140336374 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS - The present invention relates to a process for the production of novel antagonists for CCR2 (CC chemokine receptor 2) and intermediates thereof. | 11-13-2014 |
| 20140335175 | Extended Release Tablet Formulation Containing Pramipexole or a Pharmaceutically Acceptable Salt Thereof - An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch. | 11-13-2014 |
| 20140335052 | COMBINATION THERAPY FOR TREATING HCV INFECTION IN AN HCV-HIV COINFECTED PATIENT POPULATION - The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient that is co-infected with HIV. | 11-13-2014 |
| 20140331994 | SYSTEM COMPRISING A NEBULIZER AND A PACKAGING - A system comprising a nebulizer, in particular inhaler, having a pre-installed container is proposed. The system comprises a packaging preventing fluidic connection or opening of the container in a delivery state of the nebulizer. | 11-13-2014 |
| 20140323492 | CCR2 RECEPTOR ANTAGONISTS - The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. | 10-30-2014 |
| 20140323468 | ALDOSTERONE SYNTHASE INHIBITORS - The present invention relates to compounds of formula (I): | 10-30-2014 |
| 20140323447 | HETEROAROMATIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF - The present invention relates to compounds of general formula (I) | 10-30-2014 |
| 20140315882 | PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The invention relates to new pyrrolidine derivatives of the formula | 10-23-2014 |
| 20140315832 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus. | 10-23-2014 |
| 20140303194 | SALT FORMS OF ORGANIC COMPOUND - The present invention relates to novel salt forms of a certain DPP-4 inhibitor and their use in pharmaceutical compositions useful in the treatment of type 2 diabetes, as well as their production. | 10-09-2014 |
| 20140303098 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD). | 10-09-2014 |
| 20140303097 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes. | 10-09-2014 |
| 20140296230 | DIHYDROQUINAZOLINONE ANALOGUES - The present invention encompasses compounds of general formula (I) | 10-02-2014 |
| 20140296229 | INDOLINONE ANALOGUES - The present invention encompasses compounds of general formula (I) | 10-02-2014 |
| 20140296217 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES - The present invention relates to the use of indolinones of general formula | 10-02-2014 |
| 20140294995 | Lozenge for treating sore throat, hoarseness and associated dry cough, and inflammatory diseases of the oral and pharyngeal cavity - The present invention relates to a pharmaceutical formulation containing a combination of (a) at least one astringent active substance and (b) at least one mucilaginous drug and the use thereof for the prevention or treatment of inflammatory diseases of the oropharyngeal region and for the treatment of painful irritations of the mucosa in the oropharyngeal region and associated irritable cough. | 10-02-2014 |
| 20140275579 | NOVEL PROCESS FOR THE MANUFACTURE OF 3-OXO-TETRAHYDROFURAN - This invention relates to a novel method for the preparation of 3-oxo-tetrahydrofuran comprising oxidizing 3-hydroxy-tetrahydrofuran in the presence of a catalytic amount of 2,2,6,6-tetramethyl-piperidine-N-oxyl (TEMPO) with trichloroisocyanuric acid. | 09-18-2014 |
| 20140275159 | SUBSTITUTED 2-AZA-BICYCLO[2.2.2]OCTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C - This invention relates to 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 | 09-18-2014 |
| 20140275155 | SUBSTITUTED BICYCLIC 1-CARBOXYLIC-ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C - This invention relates to bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides of formula 1 | 09-18-2014 |
| 20140275114 | SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C - This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides of formula 1 | 09-18-2014 |
| 20140275025 | SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C - This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid(benzyl-cyano-methyl)-amides of formula 1 | 09-18-2014 |
| 20140275014 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS - The present invention encompasses compounds of the formula (I) | 09-18-2014 |
| 20140275012 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS - The present invention encompasses compounds of the formula (I) | 09-18-2014 |
| 20140274890 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY - The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin. | 09-18-2014 |
| 20140274889 | CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY - The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk. | 09-18-2014 |
| 20140271544 | COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE SUB-POPULATION - The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in patients having genetic variations located near the IL28B gene, including SNP rs12979860 with a non-CC genotype and SNP rs8099917 with a non-TT genotype. | 09-18-2014 |
| 20140256624 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The invention relates to a pharmaceutical composition according to the claim | 09-11-2014 |
| 20140255413 | Combination therapy for neoplasia treatment - The present invention relates to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate cancer, and particularly CRPC, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide. | 09-11-2014 |
| 20140249129 | Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity - This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 | 09-04-2014 |
| 20140248665 | NOVEL INTRON SEQUENCES - The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns. | 09-04-2014 |
| 20140248660 | HETEROLOGOUS INTRON WITHIN A SIGNAL PEPTIDE - The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns. | 09-04-2014 |
| 20140247062 | Device and method to measure the permeation rate of a packaging - A device for determining the average layer thickness l of a planar packaging material for pharmaceutical packaging, particularly blisters and/or bottles, by means of a capacitive measurement, in which the opposing outer surfaces of the packaging material are provided with electrodes. | 09-04-2014 |
| 20140242637 | ARTIFICIAL INTRONS - The invention concerns the field of recombinant gene engineering. It concerns novel artificial introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel artificial intron sequences. | 08-28-2014 |
| 20140242029 | COMBINATION THERAPY FOR TREATING HCV INFECTION IN AN HCV-HIV COINFECTED PATIENT POPULATION - The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient that is co-infected with HIV. | 08-28-2014 |
| 20140235661 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF - The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. | 08-21-2014 |
| 20140235627 | 2-ADRENOCEPTOR AGONIST FOR IMPROVEMENT OF EXERCISE TOLERANCE - This invention relates to the β2-adrenoceptor agonist Olodaterol or a pharmaceutically acceptable salt thereof, | 08-21-2014 |
| 20140234893 | HETEROLOGOUS INTRON WITHIN AN IMMUNOGLOBULIN DOMAIN - The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns. | 08-21-2014 |
| 20140221373 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE - The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein A | 08-07-2014 |
| 20140221349 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS - Compounds of general formula I | 08-07-2014 |
| 20140221335 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY - This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 | 08-07-2014 |
| 20140213787 | REGIOSELECTIVE PREPARATION OF 2-AMINO-5-TRIFLUOROMETHYLPYRIMIDINE DERIVATIVES - The present invention relates to a method of making 2,4-differentiated 5-trifluoromethylpyrimidines, which are useful as intermediates in the manufacture of active pharmaceutical substances. | 07-31-2014 |
| 20140213568 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof - The invention relates to new pyrrolidine derivatives of the formula | 07-31-2014 |
| 20140206674 | COMBINATIONS WITH 2-AMINOETHANESULFONIC ACID - The invention relates to a pharmaceutical combination of 2-aminoethanesulfonic acid with a pharmaceutical agent such as an antihypertensive agent and the use of 2-aminoethanesulfonic acid in a method to lower the bilirubin level in the blood. | 07-24-2014 |
| 20140205611 | MONOCLONAL ANTIBODIES THAT BIND TO HGM-CSF AND MEDICAL COMPOSITIONS COMPRISING SAME - Disclosed herein are anti-hGM-CSF monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hGM-CSF activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided. The present invention is useful for the treatment of various diseases that are associated with aberrant expression of hGM-CSF. | 07-24-2014 |
| 20140205592 | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors - The present invention relates to a method for determining whether a cancer patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor, comprising detecting the expression of the E-cadherin protein in a cancer sample of said cancer patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. Said detection of the expression of the E-cadherin protein in a cancer sample of a cancer patient is preferably conducted by way of an immunohistochemistry (IHC) method. Said IHC method preferably employs a primary antibody which is specific for E-cadherin and a secondary antibody which specifically reacts with the primary antibody. The present invention also relates to a method of treating a cancer patient whose cancer is characterized by an E-cadherin protein immunoreactivity score (IRS) of 0-2, comprising administering to the patient a therapeutically effective amount of a PTK2 inhibitor. In a further aspect, the present invention relates to a PTK2 inhibitor for use in the treatment of a cancer patient whose cancer is characterized by an E-cadherin protein immunoreactivity score (IRS) of 0-2. The present invention also provides a method of screening for a therapeutically effective PTK2 inhibitor comprising the steps of (a) providing cancer cells or a cancer cell line which are characterized by an E-cadherin protein immunoreactivity score of 2, 1, or 0 (1 being preferred and 0 being even more preferred); (b) contacting the cancer cell or the cancer cell line of (a) with a PTK2 inhibitor; and (c) evaluating whether the PTK2 inhibitor negatively affects the cancer cell/cancer cell lines. In a further aspect, the present invention relates to a method for stratifying cancer patients that are susceptible to treatment with a PTK2 inhibitor, comprising determining the E-cadherin IRS score in a cancer sample of said patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 (i.e. 2, 1, or 0) indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. The present invention also relates to a pharmaceutical package comprising a PTK2 inhibitor, and (a) instructions and/or an imprint indicating that said PTK2 inhibitor is to be used for the treatment of patients which suffer from a cancer which is characterized by an E-cadherin protein immunoreactivity score of 2, 1, or 0 (1 being preferred and 0 being more preferred); and/or (b) instructions and/or an imprint indicating that said patient is to be stratified by a method of the present invention; and/or (c) means to carry out a method as defined herein. | 07-24-2014 |
| 20140199298 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS - The invention relates to a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amounts of:
| 07-17-2014 |
| 20140194442 | ANTICANCER THERAPY - The invention describes anti-cancer therapies comprising using dual Aurora kinase/MEK inhibitors as described herein. | 07-10-2014 |
| 20140193433 | BCMA-BASED STRATIFICATION AND THERAPY FOR MULTIPLE MYELOMA PATIENTS - The present invention relates to methods for the stratification of a multiple myeloma (MM) patient comprising determining whether or not B-cells, preferably malignant B-cells of said patient express BCMA protein on their surface. Also, methods for selecting an antibody-based multiple myeloma (MM) therapy is based on whether or not BCMA is expressed on the cell surface of B-cells, preferably malignant B-cells of a patient. Furthermore, antibody-based therapies for patients who have BCMA positive malignant B-cells are provided. | 07-10-2014 |
| 20140190472 | RESERVOIR FOR NEBULIZER WITH A DEFORMABLE FLUID CHAMBER - A reservoir for a nebulizer, and a nebulizer with a reservoir in which, to avoid undesirable rises in pressure, a fluid chamber of the reservoir is pre-collapsed and filled with an initial amount of fluid which is less than the maximum volume of the fluid chamber. Preferably, before being filled, the fluid chamber is compressed and/or expanded by means of gas to a defined volume which is less than the maximum volume of the fluid chamber. | 07-10-2014 |
| 20140187779 | Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoylamino)benzyl]pyrimid- in-5-yl]acetic acid - The present invention relates to a process for preparing a compound of formula (I). | 07-03-2014 |
| 20140187563 | COMBINATION THERAPY IN TREATMENT OF ONCOLOGICAL AND FIBROTIC DISEASES - The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of an inhibitor of vascular endothelial growth factor receptors (VEGFRs) in conjunction with a thrombin inhibitor. | 07-03-2014 |
| 20140187539 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS - Heteroaryloxy-substituted benzoic acid amides of general formula I | 07-03-2014 |
| 20140182587 | INHALATOR AND CAPSULE FOR AN INHALATOR - The invention relates to a capsule for receiving a preferably powdered pharmaceutical preparation and an inhaler in which, for inhalation, the preparation is expelled from the capsule through at least one hole. A capsule according to the invention comprises as capsule elements a capsule cap and a capsule body, at least one of which comprises at least one prefabricated hole. | 07-03-2014 |
| 20140179907 | ANTI-CD40 ANTIBODIES - The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same. | 06-26-2014 |
| 20140179669 | Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use - The present invention relates to compounds defined by formula I | 06-26-2014 |
| 20140178401 | ANTI-IL-23 ANTIBODIES - The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies, pharmaceutical compositions and therapeutic and diagnostic methods and compositions for using the same. | 06-26-2014 |
| 20140171692 | PROCESS FOR ASYMETRIC METHYLALLYLATION IN THE PRESENCE OF A 2,2'-SUBSTITUTED 1,1'-BI -2-NAPHTHOL CATALYST - Disclosed are a process and catalysts useful for carrying out asymmetric methlyallylations. The catalysts used in the invention have the formula (IV): wherein X | 06-19-2014 |
| 20140171641 | PROCESS FOR MAKING N-SULFINYL a-AMINO AMIDES - Disclosed is a process for making diastereomeric N-sulfinyl α-amino amides by reaction of chiral sulfinimines with formamides and lithium diisopropylamide. The process of the invention provides the N-sulfinyl α-amino amides in high yields and with high diastereoselectivity. | 06-19-2014 |
| 20140163040 | Pharmaceutical dosage form for immediate release of an indolinone derivative - The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate. | 06-12-2014 |
| 20140163025 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS - The present invention relates to compounds of general formula I, | 06-12-2014 |
| 20140158118 | NEBULIZER - A nebulizer for a fluid, particularly for medical aerosol treatment is proposed. To allow easier operation and confer improved operational reliability a sealed container holding the fluid is already arranged in the nebulizer when it is supplied and the nebulizer is constructed so that the container is opened inside the nebulizer before or during the first use of the nebulizer. For this purpose, a transportation lock is provided for the sealed container which, in the delivery state, is in engagement with the sealed container in a manner preventing the sealed container from moving axially in the nebulizer. | 06-12-2014 |
| 20140154304 | COMBINATION THERAPY WITH VOLASERTIB - Disclosed is the use of Volasertib or a salt or a hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) comprising administering a high dose of Volasertib in combination with fludarabine, cytarabine and Granulocyte colony-stimulating factor (GCSF) or in combination with fludarabine, cytarabine, GCSF and a daunorubicin citrate liposome injection. | 06-05-2014 |
| 20140148492 | BICYCLOSUBSTITUTED PYRAZOLE COMPOUNDS FOR TREATING HAIR LOSS - The present invention relates to compounds of formula (Ia) or (Ib) or pharmaceutically acceptable salts thereof for use in the treatment or prevention of hairloss, | 05-29-2014 |
| 20140148484 | PYRAZOLE COMPOUNDS FOR TREATING HAIRLOSS - The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof for use in the treatment or prevention of hairloss, | 05-29-2014 |
| 20140148470 | PYRIMIDINE COMPOUNDS FOR TREATING HAIRLOSS - The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof for use in the treatment or prevention of hairloss, | 05-29-2014 |
| 20140148462 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS - The present invention relates to compounds of general formula I, | 05-29-2014 |
| 20140142135 | 4-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS - The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, | 05-22-2014 |
| 20140142098 | TRIAZOLOPYRAZINE - Disclosed are compounds of the formula (I) | 05-22-2014 |
| 20140135506 | PROCESS FOR MAKING NOVEL CHIRAL PHOSPHORUS LIGANDS - Disclosed are methods for making chiral phosphorus ligands including chiral phosphines, chiral phosphine oxides, phosphonamides, and aminophosphines. The chiral phosphorus ligands prepared by the methods of the invention are useful as components of chiral catalysts, e.g., transition metal complexes. | 05-15-2014 |
| 20140135497 | SYNTHESIS OF 2,4-DICHLORO-5-TRIFLUOROMETHYL-PYRIMIDINE - This invention relates to a novel method for the synthesis of 2,4-dichloro-5-trifluoromethyl-pyrimidine useful as intermediate in the manufacture of pharmaceutically active ingredients. | 05-15-2014 |
| 20140135495 | STEREOSELECTIVE SYNTHESIS OF BICYCLIC HETEROCYCLES - The present invention relates to a process for the stereoselective preparation of compounds of formulae (1A) and (1B) | 05-15-2014 |
| 20140135493 | METHODS OF MAKING DIASTEREOMERIC ORGANIC COMPOUNDS - Disclosed is a process for making diastereomeric compound of the formula (I): wherein m, n and R | 05-15-2014 |
| 20140135348 | USES OF DPP IV INHIBITORS - The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments. | 05-15-2014 |
| 20140135336 | TRIAZOLOPYRIDAZINE - Disclosed are compounds of general formula (I) | 05-15-2014 |
| 20140135309 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS - This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I | 05-15-2014 |
| 20140135307 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS - This invention relates to co-crystals and salts of CCR3 inhibitors of formula 1, | 05-15-2014 |
| 20140128604 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS - The present invention relates to substituted xanthines of general formula | 05-08-2014 |
| 20140128578 | SELECTIVE ENRICHMENT OF ANTIBODIES - The invention relates to a process for the selective concentration of immunoglobulins or other proteins that contain an Fc domain (target protein), comprising the following steps:
| 05-08-2014 |
| 20140128409 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES - The present invention relates to the use of indolinones of general formula | 05-08-2014 |
| 20140121234 | INHALANT PROPELLANT-FREE AEROSOL FORMULATION - The invention relates to inhalant propellant-free aerosol formulations containing at least one inert, non-volatile auxiliary substance for adjusting defined droplet sizes. | 05-01-2014 |
| 20140120095 | BISPECIFIC BINDING MOLECULES FOR ANTI-ANGIOGENESIS THERAPY - Bispecific binding molecules, in particular immunoglobulin single variable domains such as VHHs and domain antibodies, comprising a VEGF-binding component and a DII4-binding component in one molecule. Pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF- and DII4-mediated effects on angiogenesis. Nucleic acids encoding the bispecific binding molecules, host cells and methods for preparing same. | 05-01-2014 |
| 20140114089 | NOVEL PROCESS FOR THE MANUFACTURE OF 4-AMINOBENZOAMIDINE DIHYDROCHLORIDE - The present invention relates to a process for the preparation of 4-aminobenzoamidine (4-AMBA) salts of general formula (I) | 04-24-2014 |
| 20140113917 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS - The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2 antagonistic activity, wherein L, Y | 04-24-2014 |
| 20140107343 | INDENOPYRIDINE DERIVATIVES - Disclosed is a compound of formula (I) | 04-17-2014 |
| 20140107103 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES - Dihydrothienopyrimidinesulphoxides of formula 1 | 04-17-2014 |
| 20140106324 | SYSTEM, METHOD, USE AND INFORMATION STORAGE MEDIUM FOR PRACTICING OF AN INHALATION PROCESS - An inhalation training system and a method for practicing of an inhalation process and a method of operating a portable communications device in this respect and to an information storage medium are improved. An air flow during inhalation is converted into an acoustic signal, especially a whistling tone. The acoustic signal is picked up by a microphone of a portable communications device, such as a smartphone, and is electronically evaluated. The inhalation training system has a mouthpiece and a converter apparatus for converting the air flow into the acoustic signal and in addition has a holding apparatus for especially detachable holding of the communications device. | 04-17-2014 |
| 20140100292 | Use of moisture-conditioned disintegrants or expanding agents in tablet manufacture for the selective adjustment of the mechanical properties, the dissolving kinetics and/or the water loading of the tablets - The present invention relates inter alia to the use of moisture-conditioned disintegrants or expanding agents in tablet manufacture for the selective adjustment of the mechanical properties, the dissolution kinetics (dissolution) and/or the water loading of tablets. | 04-10-2014 |
| 20140100236 | Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets - The present invention relates inter alia to the use of selectively moisture-adjusted tabletting material in the preparation of mechanically stable oral tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing oral tablets. | 04-10-2014 |
| 20140100222 | Beta2-ADRENOCEPTOR AGONIST FOR THE TREATMENT OF COUGH - This invention relates to the β2-adrenoceptor agonist Olodaterol or a pharmaceutically acceptable salt thereof, | 04-10-2014 |
| 20140100211 | New pyrrolidine derivatives, pharmaceutical compositions and uses thereof - Pyrrolidine derivatives of the formula | 04-10-2014 |
| 20140094523 | SOLID AMBROXOL-CONTAINING PREPARATION - The present invention relates to solid preparations containing ambroxol which are obtainable by melt extrusion of the mixture consisting of a) 30 to 80% by weight of ambroxol hydrochloride, b) 2 to 68% by weight of at least one hydrogenated vegetable oil, c) 2 to 68% by weight of at least one mixture containing fatty acid ester and/or hydroxy fatty acid ester and d) 0 to 66% by weight of one or more pharmaceutical adjuvants, based in each case on the total amount of the preparation and its use for secretolytic treatment in acute and chronic bronchopulmonary diseases. | 04-03-2014 |
| 20140093499 | PHARMACEUTICAL COMBINATIONS COMPRISING DUAL ANGIOPOIETIN-2 / DLL4 BINDERS AND ANTI-VEGF AGENTS - The present invention relates to pharmaceutical combinations comprising dual Angiopoietin-2/Dll4 binders and anti-VEGF agents for use in treating diseases like cancer and ocular diseases. | 04-03-2014 |
| 20140093498 | PHARMACEUTICAL COMBINATIONS COMPRISING DUAL ANGIOPOIETIN-2 / DLL4 BINDERS AND ANTI-VEGF-R AGENTS - The present invention relates to pharmaceutical combinations comprising dual Angiopoietin-2/DII4 binders and anti-VEGF-R agents for use in treating diseases like cancer and ocular diseases. | 04-03-2014 |
| 20140088097 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF - The present invention relates to compounds of general formula (I) | 03-27-2014 |
| 20140088027 | PHARMACEUTICAL COMPOSITION COMPRISING AN SGLT2 INHIBITOR AND A PPAR- GAMMA AGONIST AND USES THEREOF - The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor and a PPARγ agonist which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions. | 03-27-2014 |
| 20140087996 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The invention relates to a pharmaceutical composition according to the claim | 03-27-2014 |
| 20140083423 | VIBRATING BLISTER - Disclosed is an inhaler and a method for using the inhaler for the inhalation of a formulation from a carrier. The carrier contains the formulation in a receptacle and is set oscillating by an air current. An improved or defined delivery and nebulisation of the preferably powdered formulation is made possible by the fact that the carrier is set oscillating in defined manner, the formulation is dispensed through a cover element having three to five holes and/or the air current flows onto a fin associated with the carrier and flows past at least substantially only one flat side of the carrier. | 03-27-2014 |
| 20140080757 | GLUCAGON ANALOGUES - The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 03-20-2014 |
| 20140079781 | PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and pioglitazone, processes for the preparation thereof, and their use to treat certain diseases. | 03-20-2014 |
| 20140073641 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS - The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, wherein i.) the nitrogen atom of the pyrazolo-group that is next to the pyrimidino-group is attached to a non-aromatic, organic heterocycle having at least one ring hetero atom selected from O, N and S and ii.) to the C-atom between the two nitrogen atoms of the pyrimidinone-ring a second substituent is bound via an optionally substituted methylene-bridge. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease. | 03-13-2014 |
| 20140073629 | ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS - The present invention relates to compounds of formula (I): | 03-13-2014 |
| 20140073621 | 5-ALKYNYL-PYRIMIDINES - The present invention encompasses compounds of general formula (1) | 03-13-2014 |
| 20140066655 | PROCESS FOR PREPARING N-H OR N-ALKYL 2-PROPYNAMIDE - Disclosed is a method for the synthesis of N—H or N-alkyl 2-propynamides useful as intermediate in the manufacture of pharmaceutically active ingredients. | 03-06-2014 |
| 20140066634 | PROCESS FOR PREPARING 6-IODO-2-OXINDOLE - Disclosed is a method for the synthesis of 6-iodo-2-oxindole useful as intermediate in the manufacture of pharmaceutically active ingredients. Also disclosed is a novel intermediate used in the synthesis of this compound. | 03-06-2014 |
| 20140066518 | USE OF A SPRAYABLE COMPOSITION COMPRISING AMBROXOL - The present invention relates to ambroxol hydrochloride for the treatment of acute pharyngitis, wherein ambroxol hydrochloride as a sprayable composition comprising up to 30 mg/ml ambroxol hydrochloride is administered locally in a dose of 1 to 20 mg. | 03-06-2014 |
| 20140066456 | COMBINATION THERAPY IN TREATMENT OF CANCER AND FIBROTIC DISEASES - The invention relates to new methods for the treatment of oncological and fibrotic diseases comprising the combined administration of a receptor tyrosine kinase inhibitor in conjunction with a thrombin inhibitor. | 03-06-2014 |
| 20140066428 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them - The present invention relates to compounds defined by formula I | 03-06-2014 |
| 20140057928 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR - This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection: | 02-27-2014 |
| 20140057926 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY - This invention relates to substituted 4-pyridones of formula 1 | 02-27-2014 |
| 20140057920 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY - This invention relates to substituted 4-pyridones of formula 1 | 02-27-2014 |
| 20140057916 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY - This invention relates to substituted 4-pyridones of formula 1 | 02-27-2014 |
| 20140057898 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS - The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations. | 02-27-2014 |
| 20140051728 | DABIGATRAN IN TUMOR THERAPY - The invention relates to a new use of dabigatran etexilate of formula I | 02-20-2014 |
| 20140051674 | NEW COMPOUNDS - The present invention encompasses compounds of general formula (1) | 02-20-2014 |
| 20140046046 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE - Glucopyranosyl-substituted benzene derivatives of general formula I | 02-13-2014 |
| 20140045898 | METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY - A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient a dosage of >150 mg b.i.d. to 300 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof. | 02-13-2014 |
| 20140045857 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes - The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention. | 02-13-2014 |
| 20140045856 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes - The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention. | 02-13-2014 |
| 20140045823 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF - The present invention relates to compounds of general formula I, | 02-13-2014 |
| 20140045813 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS - The present invention encompasses compounds of the formula (I) | 02-13-2014 |
| 20140039203 | Process for preparing spiro[2.5]octane-5,7-dione - Disclosed is a method for the synthesis of spiro[2.5]octane-5,7-dione useful as intermediate in the manufacture of pharmaceutically active ingredients. Also disclosed are novel intermediates used in the synthesis of this compound. | 02-06-2014 |
| 20140039189 | NOVEL PROCESS FOR THE PREPARATION OF ACYLGUANIDINES AND ACYLTHIOUREAS - The present invention relates to a novel process for the preparation of compounds of general formula (I) | 02-06-2014 |
| 20140038993 | NEW COMPOUNDS - The present invention includes compounds of general formula ( | 02-06-2014 |
| 20140038911 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The invention relates to a pharmaceutical composition according to the claim | 02-06-2014 |
| 20140038888 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS - The invention relates to a pharmaceutical composition comprising 1.a and/or 1.b according to claim | 02-06-2014 |
| 20140037719 | STABILIZED PHARMACEUTICAL FORMULATIONS OF A POTENT HCV INHIBITOR - Described are various methods for stabilizing pharmaceutical formulations of a specific Hepatitis C Viral (HCV) inhibitor against the formation of a particular genotoxic degradation product. Such methods include temperature control, moisture control, excipient control, capsule shell control, basification and a reconstitution approach. | 02-06-2014 |
| 20140031544 | ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE - The present invention relates to compounds defined by formula I | 01-30-2014 |
| 20140031369 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF - The present invention relates to compounds of general formula I, | 01-30-2014 |
| 20140031343 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS - Drug combinations which contain a PDE4-inhibitor and a non-steroidal anti-inflammatory drug (NSAID), processes for preparing them, and their use in treating in particular respiratory complaints such as COPD, chronic sinusitis, and asthma. The PDE4 inhibitors of the drug combinations include compounds of general formula 1 | 01-30-2014 |
| 20140031339 | INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to compounds of formula (I): | 01-30-2014 |
| 20140031301 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions. | 01-30-2014 |
| 20140030275 | A-BETA BINDING POLYPEPTIDES - The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease. | 01-30-2014 |
| 20140024628 | FUMARIC ACID SALT OF 9-[4-(3-CHLORO-2-FLUORO-PHENYLAMINO)-7-METHOXY-QUINAZOLIN-6-YLOXY]-1,4-DI- AZA-SPIRO[5.5]UNDECAN-5-ONE, ITS USE AS A MEDICAMENT AND THE PREPARATION THEREOF - The present invention relates to a compound of formula (I), | 01-23-2014 |
| 20140018405 | Anticancer Compounds - The invention describes dual Aurora kinase/MEK inhibitors and their use in therapy. | 01-16-2014 |
| 20140018372 | CRYSTALLINE FORM OF A INDOLINONE DERIVATIVE AND ITS USE - A crystalline form of 3-{3-[1-(4-Dimethylaminomethyl-phenylamino)-1-phenyl-meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-6-yl}-propynoic acid ethylamide. | 01-16-2014 |
| 20140010808 | ANTI CD37 ANTIBODIES - Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology. | 01-09-2014 |
| 20140005154 | 6,7-Dihydrothieno[3,2-d]pyrimidine for the Treatment of Inflammatory Diseases | 01-02-2014 |
| 20140004187 | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative | 01-02-2014 |
| 20140004110 | ANTI CD37 ANTIBODIES | 01-02-2014 |
| 20130345262 | METHOD FOR PREVENTION OF STROKE - A method for administering Dabigatran, optionally in the form of a pharmaceutically acceptable salt thereof, to a patient in need of an anticoagulant and/or antithrombotic medicament wherein the daily dose is determined by the dosage regimen including one measurement of dabigatran plasma level. | 12-26-2013 |
| 20130345195 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to compounds of formula (I): | 12-26-2013 |
| 20130331560 | METHODS AND DEVICES FOR PRODUCING BIOMOLECULES - A scalable process and device for producing a biomolecule, in particular pharmaceutical grade plasmid DNA. The process includes the steps of alkaline lysis and a neutralization. For separating the lysate and the precipitate, the mixture is allowed to gently flow downward through a clarification reactor that is partially filled, in its lower part, with retention material like glass beads, whereby the precipitate is retained on top of and within the retention. In a preferred embodiment of the lysis step, cell suspension and alkaline lysis solution flow through a lysis reactor that is filled with particulate material like glass beads. The process can be run continuously and fully automated. | 12-12-2013 |
| 20130331410 | 2,3-DIHYDROFURO[2,3-c]PYRIDIN-2-YLPIPERIDINE DERIVATIVES - The present invention relates to compounds of general formula I, | 12-12-2013 |
| 20130331391 | VIRAL POLYMERASE INHIBITORS - Compounds of formula I: | 12-12-2013 |
